EMA reviewing Durata's dalbavancin

EMA accepted for review an MAA from Durata Therapeutics Inc. (NASDAQ:DRTX) for dalbavancin ( RQ-00000002) to treat complicated skin and soft tissue infections (cSSTI) caused by susceptible Gram-positi...